Supernus Pharmaceuticals Ends UBS Credit Line Ahead of Indivior Combination

Supernus terminated its uncommitted, demand revolving credit line with UBS Bank USA on October 20, 2026. The agreement ended ahead of its planned combination with Indivior and an expected new senior secured credit facility for the combined company.